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Introduction
Histopathology is a data-rich discipline. A standard 
histo  pathology report describing the macroscopic, 
micro  scopic, and basic molecular features of a breast 
cancer resection specimen contains tens of individual 
data items, including the histological type, size, grade, 
completeness of excision, node status, presence or 
absence of pre-invasive disease, oestrogen receptor (ER) 
and human epidermal growth factor receptor (HER)2 
status, and sometimes a comment on response to pre-
operative systemic therapy, to name a few. When this 
information is combined with clinical parameters such as 
age and co-morbidities, clinicians can, with remarkable 
accuracy, determine what the likely outcome is for an 
individual patient, and tailor treatment accordingly. 
However, in spite of thousands of articles documenting 
and claiming reﬁ  nement of the morphological charac  ter-
isation of breast cancers using single marker prognostic 
or predictive tissue biomarkers, only ER and HER2 are 
routinely used in clinical practice as predictive bio-
markers of response to endocrine therapy and trastu  zu-
mab, respectively [1]. Markers of proliferation, such as 
measurement of the Ki67 antigen, may oﬀ  er additional 
information but have yet to gain wide acceptance [2]. 
When performed at its best, basic histopathological 
exami  nation of breast cancer remains the gold standard 
in determining patient outcome in breast cancer. Given 
the relative lack of success of new molecular clinical tests 
and the expansion of targeted therapies available to 
breast cancer patients, it seems timely to ask ourselves 
why tissue biomarkers fail to make a clinical impact, and 
to explore alternative strategies for biomarker discovery 
and individualised therapy.
From candidate pathology to systems pathology
Th  e most common type of study demonstrating the 
eﬀ  ective  ness of a biomarker for prognosis or prediction 
of response to therapy in breast cancer is based on the 
candidate approach (‘candidate pathology’). Sometimes, 
although by no means always, a candidate or group of 
candidate molecular targets are selected on the basis of a 
biological hypothesis that the molecule will in some way 
inﬂ   uence the biology of breast cancer, that is, by 
promoting apoptosis or reducing cellular proliferation. 
Th   ese hypotheses are sometimes informed by supporting 
studies  in vitro or  in vivo, but often the candidates 
represent the ‘favourite’ molecules of an investigator or 
laboratory. Th   e past few years in particular have seen an 
explosion in the number of studies taking this approach, 
facilitated by the ready application of immunohisto  chem-
istry to tissue microarrays, which allow the simultaneous 
analysis of hundreds of tissue samples on a single glass 
slide [3]. Developing biomarkers based on solid biological 
reasoning has clearly been successful in a handful of 
cases - ER and HER2 most notably, and in ovarian cancer 
the exploitation synthetic lethality by poly(ADP-ribose) 
polymerase (PARP) inhibition in BRCA mutant tumours 
illustrates elegant rational predictive biology [4]. 
However, in the majority of cases these studies fail to 
make a long-term impact and are consigned to the litera-
ture archives without ever making it as far as independent 
validation, let alone clinical trials or the clinic.
Th  e second most common type of study takes an un-
biased approach to biomarker discovery using high-
through  put methodologies, such as gene expression 
microarrays, to ﬁ  nd statistical associations to deﬁ  ne the 
bio  logical characteristics (or diﬀ  erences) between cancers 
or to ﬁ  nd statistical associations in the expression of genes, 
or groups of genes, and clinical outcome. Th  is  ‘systematic 
pathology’ approach has resulted in a deeper under-
standing of the heterogeneity of breast cancer [5], which 
has driven tailoring of therapy and new clinical trials for 
breast cancer subgroups, such as platinum-based therapy 
in triple-negative tumours, which are enriched for basal-
like cancers [6]. Th   is strategy has also led to the develop-
ment of successful clinical tests, such as the OncotypeDX 
platform, which predicts long-term risk of recurrence in 
ER+, node-negative breast cancer, and which can help 
guide the decision on which patients to give chemotherapy 
to in the setting of early breast cancer [7].
However, in spite of the successes outlined above, the 
candidate and systematic pathology approaches also have 
their limitations. For example, HER2 has a relatively high  © 2010 BioMed Central Ltd
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value; that is, it is good at selecting patients who will not 
respond to trastuzumab, but poor at selecting those who 
will [8,9]. Th  is is because single target biomarkers are 
only one species in the complex signalling networks in 
which they participate [10]. Th  is is exempliﬁ  ed by the 
signalling networks downstream of the HER2 receptor, 
particularly the phosphoinositol 3-kinase (PI3K) pathway, 
which when aberrantly activated (either through loss of 
PTEN or mutation of PIK3CA, which are frequent events 
in breast cancer and occur independently of HER2 
ampliﬁ  cation) contribute to trastuzumab resistance and 
insensitivity to other HER2-targeted therapies, such as 
pertuzumab [11]. Th  erefore, at the very least, eﬀ  ective 
predictive tests probably need to be multivariate and 
multi  plexed in order to capture network complexity on 
an individual tumour basis.
Secondly, independent validation of biomarkers in 
appropriately powered clinical cohorts is often lacking, in 
spite of excellent recommendations and guidelines for 
robust validation of tissue biomarkers [12,13]. Th  e  avail-
ability of material for validation is not always forth-
coming, or the fact is that the necessary trial to test a 
particular hypothesis for a particular therapy simply does 
not exist. Prospective testing in the clinical trial setting 
can be costly (particularly for high-throughput approaches), 
time-consuming (5 to 10 years to validate results for the 
desired clinical outcomes), and tests are likely to become 
redundant quickly in the face of rapid evolution of 
targeted therapeutics. Finally, even if a biomarker is 
identiﬁ  ed as being able to stratify a patient population for 
prognosis or therapy at a statistically signiﬁ  cant level, the 
magnitude of eﬀ   ect is not always suﬃ   ciently  large  to 
warrant change to an individual patient’s treatment. For 
truly personalised therapy, either the eﬀ   ect has to be 
large or there needs to be an alter  native or comple-
mentary therapy if the individual belongs to a particular 
subgroup.
Finally, the biomarker assay itself must be robust, but 
is not always so. Antibodies must be, above all else, 
speciﬁ  c, and validated using appropriate controls, which 
must be demonstrated. Immunohistochemistry, while 
the main  stay of pathological assessment of tissue 
biomarkers, is at best only semi-quantitative and subject 
to inter- and intra-observer variation, and measurement 
of biomarkers must follow the lead of validated 
quantitative gene expression assays. Th  is may take the 
form of quantitative ﬂ  uorescence analysis systems, such 
as the AQUA system [14], which has recently been 
recommended as a promis  ing strategy for ER measure-
ment by the National Compre  hensive Cancer Network 
(NCCN) Task Force report [15] due to superior 
sensitivity, reproducibility, and quantiﬁ  cation. Further-
more, biomarkers that show a large degree of tissue 
variability, due to either biological or artefactual 
heterogeneity, are unlikely to be repro  ducible.
So what can be done to complement the candidate and 
systematic pathology approaches, in order to overcome 
some of their limitations and streamline biomarker 
discovery? Recently, the nascent ﬁ  eld of systems biology 
has entered the scientiﬁ  c lexicon as a promising strategy 
to understand complex biological systems [10,16,17]. 
Cancer is the archetypal complex system; each tumour is 
hardwired by diﬀ  erent underlying genomic aberrations, 
cellular signalling represents a massively complex set of 
non-linear networks connected by feed-forward and 
feedback loops, each cell and tumour is spatially hetero-
geneous with respect to intracellular compartments (that 
is, nucleus, cytoplasm, intracellular organelles) and the 
extracellular environment (stroma, blood vessels, 
immediate microenvironment, oxygen tension) and the 
entire tissue is inﬂ  uenced by the host (that is, endocrine 
and immune systems, circulating factors, and meta  bo-
lomics) [18]. Diﬀ  erences may also exist when the tumour 
spreads from the primary to distant sites [19]. Although 
systems biology deﬁ  es accurate deﬁ  nition, for the purposes 
of this commentary, a systems biology approach includes a 
degree of mathematical modelling of biological complexity 
in order to describe changes in biology over time. Systems 
pathology is the application of these methods to human 
disease, and in particular breast cancer.
Systems pathology in breast cancer
In spite of the successful application of systems biology to 
other areas of clinical medicine, such as predicting the 
side eﬀ  ects of the drug ranolazine on the heart [20,21], 
systems biology has failed to gain widespread acceptance 
within the clinical academic community. Th   is is perhaps 
surprising, since other abstractions of biology, which help 
to make complexity of disease more understandable, are 
accepted and commonplace. For instance, cancer cell 
culture systems help us to understand basic biological 
process and test biological hypotheses, even though they 
are not an absolute representation of cancer (epithelium, 
stroma blood vessels, and so on) itself. An additional 
problem is that there are relatively few ‘success stories’ of 
the useful application of systems biology to cancer 
medicine. So where might systems pathology be useful in 
breast cancer?
As stated above, although signalling in cancer is often 
represented by simple linear pathways, the reality is that 
signalling is complex and non-linear, with multiple levels 
of crosstalk and feedforward and feedback loops, which 
results in robust networks insensitive to perturbation, 
that is, therapy. Th   erefore, while cancer might be diﬃ   cult 
to model, the need to do so is even greater since many 
new therapies are designed to target such signalling 
pathways. Failure to do so can be costly; for example, loss 
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target of rapamycin (mTOR) inhibitors results in 
induction of AKT signalling, and may be responsible for 
the disappointing eﬃ   cacy of mTOR antagonists in the 
clinic [22]. Negative feedback signalling mechanisms are 
likely to contribute to the poor eﬃ   cacy of agents when 
studied in phase II and III cancer trials and to the high 
rate of attrition of drugs (approximately 30% due to 
eﬃ   cacy), which is both time consuming and expensive 
[23]. Empirical testing of every possible agent or combi-
nation of agents in the preclinical or clinical setting 
becomes prohibitively expensive and impractical.
Process-based models (that is, those based on our 
understanding of the network biology, versus data-driven 
models) aﬀ   ord a mechanistic representation of the 
under  lying cell dynamics and may be parameterised 
directly by experimental data. Th  ese models are formu-
lated in terms of ordinary diﬀ   erential equations that 
describe the kinetics of the concentrations of molecular 
species within the network over time.
We recently employed a process-driven approach in 
order to study resistance factors to receptor tyrosine 
kinase (RTK) inhibitors such as trastuzumab and pertu-
zumab [24]. Since the reported resistance mechanisms to 
trastuzumab seem to relate to aberrant mitogen-activated 
protein kinase (MAPK)/PI3K signalling (PIK3CA muta-
tions and inactivation of the tumor suppressor gene 
PTEN [25,26]), we reasoned that a systems analysis of 
these pathways, which are the best studied process-
driven models to date, would be a useful application of 
systems biology to a clinical problem in oncology. A new 
model of MAPK/PI3K was developed to describe HER2-
inhibitor antibody/receptor binding, HER2/HER3 
dimeri  sa  tion and inhibition, AKT/MAPK crosstalk, and 
the kinetic and regulatory properties of PTEN, and was 
based on modelling studies of the HER signalling network 
[27-30]. Th   e inclusion of the tumour suppressor protein 
PTEN was deemed particularly important since it is a key 
negative regulator of the PI3K signalling pathway. We 
demon  strated that resistance to RTK inhibitors was 
governed by the PTEN:activated PI3K ratio (integrated 
resistance factor γ), and that PTEN, appropriately 
measured in the clinical setting, could stratify patients 
for HER2 inhibitor or combinatorial therapy, particularly 
an RTK inhibitor and PI3K inhibitor in cancers with low γ. 
Th   is is one of few ‘success stories’ of how a systems biology 
approach can generate hypotheses that can be tested 
experimentally in preclinical models and that can then be 
applied to clinical evaluation. Such approaches might help 
increase the level of evidence that a particular biomarker 
might be useful within a prospective clinical trial.
Further examples of applied systems biology are 
required so that it might gain credibility and be accepted 
within the clinical community. In breast cancer, this need 
not be limited to cellular signalling. For instance, in spite 
of very accurate biochemical characterisation of the 
eﬀ  ect of cytochrome P450 enzyme polymorphisms and 
how they aﬀ  ect the rates of metabolism of tamoxifen 
[31], there is no formal mathematical description of these 
enzymatic processes. A uniﬁ   ed model of tamoxifen 
metabolism to take into account individual genetic 
variability (measured in each patient before commence-
ment of therapy) and the eﬀ  ect of dose and interacting 
agents (for example, known interactors such as selective 
serotonin reuptake inhibitors) could help tailor tamoxifen 
therapy on an individual pharmacogenomic basis. Models 
of host factors could ultimately be integrated with models 
of tumour biology (that is oestrogen signalling pathways), 
reﬁ  ning the individualised therapy approach to take into 
account drug pharmacokinetics and pharmacodynamics.
Conclusions - what is needed to make systems 
pathology reality?
Th  e above discussion highlights some opportunities for 
using new mathematical methodologies for biomarker 
identiﬁ   cation, drug target validation, and perhaps 
individualised pharmacogenomic approaches for breast 
cancer patients. Although a comprehensive description is 
outside the scope of this commentary, other mathe-
matical techniques oﬀ   er opportunities for integrating 
clinical and pathological data, such as Bayesian networks 
and fuzzy logic [10]. In tandem, because systems biology 
is a quantitative science, data generation in pathology 
needs to be reﬁ  ned and improved in order to generate 
high-quality data for systems pathology, which may come 
in the form of quantitative protein assays such as reverse 
phase protein arrays, quantitative immunoﬂ  uorescence, 
mass spectrometry, or in vivo imaging. Clinical models in 
which multiple measurements of changing disease can be 
made are essential, such as extended neoadjuvant proto-
cols with multiple biopsies or implantable devices (a ‘lab-
on-a-chip’). Finally, systems pathology is not mutually 
exclusive to other approaches used to discover or reﬁ  ne 
biomarker development, such as high-throughput 
approaches or empirical testing. Instead, systems 
pathology should be regarded as an opportunity to add 
value to data generation and generate new hypotheses 
about breast cancer biology, and increase the burden of 
evidence for the use of biomarkers in the clinic.
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